{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:03:05Z","timestamp":1759334585068,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jfo.2019.08.003","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T12:45:38Z","timestamp":1576500338000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Occlusions veineuses r\u00e9tiniennes trait\u00e9es par injections intra-vitr\u00e9ennes de b\u00e9vacizumab \u00e0 l\u2019h\u00f4pital d\u2019instruction, d\u2019application et de r\u00e9f\u00e9rence des arm\u00e9es de Yaound\u00e9"],"prefix":"10.1016","volume":"43","author":[{"given":"G.","family":"Koki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Aboubakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Biangoup Nyamsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Teperesna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Nomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ep\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Omgbwa Eball\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Bella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ebana Mvogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2019.08.003_bib0005","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jfo.2009.10.002","article-title":"Occlusions veineuses r\u00e9tiniennes\u00a0: traitement anti-VEGF","volume":"32","author":"Nghiem-Buffet","year":"2009","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0010","doi-asserted-by":"crossref","first-page":"467","DOI":"10.12688\/f1000research.12886.1","article-title":"Recent advances in understanding and managing retinal vein occlusions [version 1; referees: 3\u00a0approved]","volume":"7","author":"Esmaili","year":"2018","journal-title":"F1000\u00a0Res"},{"key":"10.1016\/j.jfo.2019.08.003_bib0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5318\/wjo.v4.i4.92","article-title":"Pathogenesis, prevention, diagnosis and management of retinal vein occlusion","volume":"4","author":"Keren","year":"2014","journal-title":"World J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0976-6677.193868","article-title":"Retinal vein occlusion","volume":"28","author":"Morris","year":"2016","journal-title":"Kerala J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4103\/0974-9233.172294","article-title":"Clinical trials in branch retinal vein occlusion","volume":"23","author":"Panakanti","year":"2016","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0030","first-page":"18","article-title":"New developments in the classification, pathogenesis, risk factors, natural history, and treatment of branch retinal vein occlusion","volume":"ID4936924","author":"Jia","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0035","first-page":"898","article-title":"Cons\u00e9quences circulatoires des occlusions veineuses r\u00e9tiniennes","volume":"25","author":"Paques","year":"2002","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0040","first-page":"26","article-title":"\u00c9pid\u00e9miologie et clinique des occlusions veineuses r\u00e9tiniennes en milieu hospitalier camerounais","volume":"19","author":"Koki","year":"2018","journal-title":"Health Sci Dis"},{"key":"10.1016\/j.jfo.2019.08.003_bib0045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0050","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.120.12.1644","article-title":"Correlation of increased vascular endothelial growth factor with neovascularisation and permeability in ischemic central vein occlusion","volume":"120","author":"Boyd","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0055","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ajo.2005.03.003","article-title":"Pathogenesis of macular oedema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6","volume":"140","author":"Noma","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0060","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/1542-8877-20050701-15","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central vein occlusion","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.jfo.2019.08.003_bib0065","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bjo.2008.141085","article-title":"Intravitreal bevacizumab (avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial","volume":"93","author":"Prager","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0070","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1001\/jama.2017.4568","article-title":"Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE 2\u00a0randomized clinical trial","volume":"317","author":"Scott","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jfo.2019.08.003_bib0075","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/IAE.0000000000001782","article-title":"Efficacy and frequency of intravitreal aflibercept versus bevacizumab for macular edema secondary to central retinal vein occlusion","volume":"38","author":"Lotfy","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2019.08.003_bib0080","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/17512433.2018.1507735","article-title":"Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis","volume":"11","author":"Sangroonguangsri","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0085","doi-asserted-by":"crossref","first-page":"e005292","DOI":"10.1136\/bmjopen-2014-005292","article-title":"Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis","volume":"4","author":"Ford","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.jfo.2019.08.003_bib0090","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2147\/OPTH.S137380","article-title":"The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions","volume":"11","author":"Ivanovska Adjievska","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0095","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1089\/jop.2017.0074","article-title":"Aflibercept versus bevacizumab and\/or ranibizumab for recurrent macular edema secondary to central retinal vein occlusion","volume":"34","author":"Ozgonul","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2019.08.003_bib0100","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.ophtha.2017.03.060","article-title":"Therapies for macular edema associated with branch retinal vein occlusion: a report by the American Academy of Ophthalmology","volume":"124","author":"Ehlers","year":"2017","journal-title":"Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/1874364101408010087","article-title":"Indications for intravitreal bevacizumab in Ibadan, Sub-saharian Africa","volume":"8","author":"Oluleye","year":"2014","journal-title":"Open Ophthalmol J"},{"key":"10.1016\/j.jfo.2019.08.003_bib0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000314718","article-title":"Retinal vein occlusion: current treatment","volume":"225","author":"Lattanzio","year":"2011","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jfo.2019.08.003_bib0115","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00417-012-2016-6","article-title":"Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review","volume":"250","author":"Yilmaz","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0120","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/jcpt.12551","article-title":"Comparaison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: a meta-analysis","volume":"42","author":"Qian","year":"2017","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jfo.2019.08.003_bib0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/1117-6806.169871","article-title":"Retinal vein occlusion in Benin City, Nigeria","volume":"22","author":"Uhumwangho","year":"2016","journal-title":"Niger J Surg"},{"key":"10.1016\/j.jfo.2019.08.003_bib0130","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ajo.2006.12.037","article-title":"Clinical, anatomic and electrphysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion","volume":"143","author":"Sivakami","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0135","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000327391","article-title":"Management of retinal vein occlusion\u2013consensus document","volume":"226","author":"Coscas","year":"2011","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jfo.2019.08.003_bib0140","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study","volume":"98","author":"Klein","year":"2000","journal-title":"Tr Am Ophthalmol Soc"},{"key":"10.1016\/j.jfo.2019.08.003_bib0145","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ophtha.2009.09.019","article-title":"Ultra-wide field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion","volume":"117","author":"Pradeep","year":"2010","journal-title":"Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3346\/jkms.2013.28.1.136","article-title":"Baseline characteristics and risk factors of retinal vein occlusion: a study by the Korean RVO Study Group","volume":"28","author":"Lee","year":"2013","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jfo.2019.08.003_bib0155","first-page":"351","article-title":"R\u00e9sultats th\u00e9rapeutiques des occlusions veineuses r\u00e9tiniennes \u00e0 Lom\u00e9 apr\u00e8s un suivi de 5\u00a0ans","volume":"56","author":"Ayena","year":"2009","journal-title":"Med Afr Noire"},{"key":"10.1016\/j.jfo.2019.08.003_bib0160","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4103\/1119-3077.134040","article-title":"Incidence and risk factors for retinal vein occlusion at the University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria","volume":"17","author":"Fiebai","year":"2014","journal-title":"Niger J Clin Pract"},{"key":"10.1016\/j.jfo.2019.08.003_bib0165","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/0974-9233.173132","article-title":"Central retinal vein occlusion: a review of current evidence\u2013based treatment options","volume":"23","author":"Patel","year":"2016","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0170","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IAE.0b013e318030e77e","article-title":"Intravitreal BEVACIZUMAB (avastin) treatment of macular edema secondary to branch retinal vein occlusion","volume":"24","author":"Rabena","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2019.08.003_bib0175","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00417-015-3130-z","article-title":"Bevacizumab treatment of macular edema in CRVO and BRVO: long term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up)","volume":"254","author":"Kornhauser","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0180","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/eye.2016.10","article-title":"Central retinal vein occlusion: modifying current treatment protocols","volume":"30","author":"Asraf","year":"2016","journal-title":"Eye"},{"key":"10.1016\/j.jfo.2019.08.003_bib0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40942-016-0045-8","article-title":"Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12\u00a0months after changing treatment from bevacizumab\/ranibiozumab \u2013 A Pilot Study","volume":"2","author":"Wirth","year":"2016","journal-title":"Int J Retin Vitr"},{"key":"10.1016\/j.jfo.2019.08.003_bib0190","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000473864","article-title":"Comparison of intravitreal ranibizumab, aflibercept, and dexamethasone implant after bevacizumab failure in macular edema secondary to retinal vascular occlusions","volume":"238","author":"Hanhart","year":"2017","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jfo.2019.08.003_bib0195","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/bjo.2007.123513","article-title":"Intravitreal bevacizumab (avastin) treatment of macular edema secondary to branch retinal occlusion","volume":"92","author":"Kreutzer","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00006982-200603000-00005","article-title":"Intravitreal Bevacizumab (avastin) treatment of macular edema in central vein occlusion: a short-term study","volume":"26","author":"Iturralde","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2019.08.003_bib0205","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bjophthalmol-2013-303121","article-title":"Two-year outcomes of intravitreal bevacizumab therapy for macular-oedema secondary to branch retinal vein occlusion","volume":"98","author":"Hikichi","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0210","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1600-0420.2006.00740.x","article-title":"Intravitreal bevacizumab treatment of macular edema due to central retinal vein occlusion","volume":"84","author":"Spandau","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.jfo.2019.08.003_bib0215","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ajo.2017.08.005","article-title":"Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with macular edema secondary to vein occlusion","volume":"182","author":"Mimouni","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.08.003_bib0220","first-page":"44","article-title":"Imaging options in retinal vein occlusions. Management of this condition should take direction from clinical trial results","author":"Relhan","year":"2018","journal-title":"Retina Today"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551219304991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551219304991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:10:13Z","timestamp":1759259413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551219304991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0181551219304991"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2019.08.003","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Occlusions veineuses r\u00e9tiniennes trait\u00e9es par injections intra-vitr\u00e9ennes de b\u00e9vacizumab \u00e0 l\u2019h\u00f4pital d\u2019instruction, d\u2019application et de r\u00e9f\u00e9rence des arm\u00e9es de Yaound\u00e9","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2019.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}